Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sector ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced in Q4 CY2024, with sales up 65.9% year on year to $658.4 million ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target reduced by Royal Bank of Canada from $165.00 to $161.00 ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

The price trend for Sarepta Therapeutics (SRPT) has been bearish lately and the stock has lost 9% over the past four weeks. However, the formation of a hammer chart pattern in its last trading ...

Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results conference call.

EST Sarepta (SRPT) files automatic mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

Reports Q4 revenue $658.4M, consensus $631.03M. “2024 performance represented the fruition of our multi-year strategy to become a ...

Over the twelve months to December 2024, Sarepta Therapeutics recorded an accrual ratio of 0.68. Statistically speaking, that's a real negative for future earnings. And indeed, during the period the ...